Intas becomes India’s first company to launch Romiplostim to treat chronic ITP
Drug-maker Intas Pharmaceuticals Ltd has become the first company to launch Romiplostim in India under the brand name Romy for the treatment of chronic Immune Thrombocytopenia (ITP). ITP is an autoimmune blood disorder which leads to low platelet counts. The newly-launched drug will cost just one-fifth of the price of the current medication. It is estimated that around 42,000 patients are diagnosed with ITP in India every year. Less than 10% of patients have access to the treatment, which is required to maintain adequate platelet counts for a longer duration.
National Policy for Rare Diseases, 2021
The Ministry of Health and Family Welfare recently approved the “National Policy for Rare Diseases...
Baloxavir can prevent spread of flu to household members: US Journal
The New England Journal of Medicine has published an article in which the researchers have claimed t...
Next Generation Biodegradable Metal Implants developed by ARCI scientists
The scientists of Advanced Research Centre for powder metallurgy and new materials along with Sree C...
India finds a tool to get deeper insight into Parkinson’s Disease
The Scientists of IIT Dhanbad and CSIR (Council of Scientific and Industrial Research) have teamed u...
Facts Box: “State of the World’s Nursing Report 2020”
The World Health Organization, Nursing Now Campaign and the International Council of Nurses released...
Topics: Blood • Branches of biology • Cytopenia • Immune thrombocytopenic purpura • Medicine • Orphan drugs • Platelet • Rare diseases • Romiplostim • Thrombocytopenia • Thrombopoietin receptor agonists • Transfusion medicine
|View All E-Books: Recent Release|